Creso Pharma


InMed Pharmaceuticals Inc.

TSE: IN


Canadian symbol: IN.TO
US symbol: INM

Currency in CAD

Valuation Measures

Market Cap (intraday) 533.73M
Enterprise Value 319.63M
Trailing P/E N/A
Forward P/E 1-3.68
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)3.87
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 7-2.61

Trading Information

Stock Price History

Beta (5Y Monthly) 1.40
52-Week Change 3-57.68%
S&P500 52-Week Change 339.22%
52 Week High 313.6950
52 Week Low 33.3500
50-Day Moving Average 34.1577
200-Day Moving Average 34.8926

Share Statistics

Avg Vol (3 month) 321.35k
Avg Vol (10 day) 320.68k
Shares Outstanding 58.05M
Implied Shares Outstanding 6N/A
Float 6.96M
% Held by Insiders 10.78%
% Held by Institutions 16.55%
Shares Short (Apr. 29, 2021) 470.66k
Short Ratio (Apr. 29, 2021) 43.61
Short % of Float (Apr. 29, 2021) 4N/A
Short % of Shares Outstanding (Apr. 29, 2021) 40.88%
Shares Short (prior month Mar. 30, 2021) 483.83k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jul. 02, 2020
Ex-Dividend Date 4N/A
Last Split Factor 21:33
Last Split Date 3Jul. 02, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun. 29, 2020
Most Recent Quarter (mrq)Dec. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-42.06%
Return on Equity (ttm)-92.87%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -7.51M
Net Income Avi to Common (ttm)-7.85M
Diluted EPS (ttm)-1.7500
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)10.02M
Total Cash Per Share (mrq)1.43
Total Debt (mrq)315.3k
Total Debt/Equity (mrq)4.15
Current Ratio (mrq)4.76
Book Value Per Share (mrq)1.08

Cash Flow Statement

Operating Cash Flow (ttm)-6.38M
Levered Free Cash Flow (ttm)-3.31M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
IN.TO
InMed Pharmaceuticals
1 day ago
IN.TO
InMed Pharmaceuticals
2 weeks ago
IN.TO
InMed Pharmaceuticals
3 weeks ago
IN.TO
InMed Pharmaceuticals
3 months ago
IN.TO
InMed Pharmaceuticals
4 months ago
IN.TO
InMed Pharmaceuticals
10 months ago
IN.TO
InMed Pharmaceuticals
12 months ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
1 year ago
IN.TO
InMed Pharmaceuticals
2 years ago
IN.TO
InMed Pharmaceuticals
2 years ago
IN.TO
InMed Pharmaceuticals
2 years ago
IN.TO
InMed Pharmaceuticals
2 years ago
IN.TO
InMed Pharmaceuticals
2 years ago
IN.TO
InMed Pharmaceuticals
2 years ago
IN.TO
InMed Pharmaceuticals
2 years ago
IN.TO
InMed Pharmaceuticals
2 years ago
IN.TO
InMed Pharmaceuticals
2 years ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Mar 2021)Next Qtr. (Jun 2021)Current Year (2021)Next Year (2022)
No. of Analysts1122
Avg. Estimate-0.32-0.36-1.34-1.14
Low Estimate-0.32-0.36-1.35-1.24
High Estimate-0.32-0.36-1.33-1.04
Year Ago EPS-0.66-0.66-2.27-1.34
Revenue EstimateCurrent Qtr. (Mar 2021)Next Qtr. (Jun 2021)Current Year (2021)Next Year (2022)
No. of Analysts1122
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings History2019-12-302020-03-302020-06-292020-12-30
EPS Est.-0.66-0.66-0.66-0.3
EPS Actual-0.66-0.66-0.44-0.53
Difference000.22-0.23
Surprise %0.00%0.00%33.30%-76.70%
EPS TrendCurrent Qtr. (Mar 2021)Next Qtr. (Jun 2021)Current Year (2021)Next Year (2022)
Current Estimate-0.32-0.36-1.34-1.14
7 Days Ago-0.32-0.36-1.34-1.14
30 Days Ago-0.33-0.36-1.35-1.15
60 Days Ago-0.33-0.37-1.36-1.16
90 Days Ago-0.33-0.37-1.53-1.47
EPS RevisionsCurrent Qtr. (Mar 2021)Next Qtr. (Jun 2021)Current Year (2021)Next Year (2022)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesIN.TOIndustrySector(s)S&P 500
Current Qtr.51.50%N/AN/AN/A
Next Qtr.45.50%N/AN/AN/A
Current Year41.00%N/AN/AN/A
Next Year14.90%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
0.78%% of Shares Held by All Insider
6.55%% of Shares Held by Institutions
6.60%% of Float Held by Institutions
22Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Bank of America Corporation12,720Dec. 30, 20200.16%52,788
Creative Planning10,990Mar. 30, 20210.14%46,707
JP Morgan Chase & Company7,472Mar. 30, 20210.09%31,756
Morgan Stanley7,122Dec. 30, 20200.09%29,556
PNC Financial Services Group, Inc.1,820Mar. 30, 20210.02%7,735
Advisor Group, Inc.936Mar. 30, 20210.01%3,978
UBS Group AG793Mar. 30, 20210.01%3,370
Reilly Financial Advisors, LLC700Mar. 30, 20210.01%2,975
AllSquare Wealth Management LLC545Mar. 30, 20210.01%2,316

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Fidelity NASDAQ Composite Index Fund4,383Mar. 30, 20210.05%18,627
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by InMed Pharmaceuticals Inc.


InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

VANCOUVER, British Columbia, May 06, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), will report financial results on Thursday, May 13, 2021 for the third quart... Read More...
InMed to Present at Canaccord Genuity's 5th Annual Global Cannabis Conference on May 11th, 2021

InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021

VANCOUVER, British Columbia, May 04, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric. A. Adams, President and CEO of InMed, will be ... Read More...
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and weeks.Anticipated study on track to begin in 3Q 2021 VANCOUVER, British Columbia, April 28, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “... Read More...
InMed Pharmaceuticals Announces Voluntary Delisting from TSX

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

VANCOUVER, British Columbia, April 27, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that, based on the strong trading data on the Nasdaq, i... Read More...
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

VANCOUVER, British Columbia, April 26, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that its IntegraSyn™ cannabinoid manufacturing approach... Read More...
InMed to Present at Virtual Conferences in March 2021

InMed to Present at Virtual Conferences in March 2021

VANCOUVER, British Columbia, March 03, 2021 -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that Er... Read More...
InMed Announces Closing of US$4.5 Million Private Placement

InMed Announces Closing of US$4.5 Million Private Placement

VANCOUVER, BC, Feb. 16, 2021 - InMed Pharmaceuticals Inc. ("InMed") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that it has closed the previously announced private placemen... Read More...
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

VANCOUVER, BC, Feb. 11, 2021 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the second quarter of fiscal... Read More...
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results

VANCOUVER, BC, Feb. 5, 2021 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"),  will report financial results for the second quarter of fiscal ye... Read More...
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

InMed's Michael Woudenberg, Karen Long & Prof. Mauro Maccarrone among Expert Speakers VANCOUVER, BC, Jan. 19, 2021 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabin... Read More...
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

TSX: IN NASDAQ: INM VANCOUVER, BC, Jan. 8, 2021 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced top-line results from its 755-... Read More...
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

TSX:IN NASDAQ:INM - Initial application with INM-088 to treat ocular disease - VANCOUVER, BC, Dec. 3, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabin... Read More...
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER, BC, Nov. 25, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced top-line results from its 755-101-HV Phase 1 clin... Read More...
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics

InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics

VANCOUVER, BC, Nov. 18, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), and BayMedica Inc., a company specializing in the design and manufa... Read More...
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering

InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering

VANCOUVER, BC, Nov. 16, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (CBN), today announced that it has closed the previously announced public offering of... Read More...
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results

InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results

VANCOUVER, BC, Nov. 13, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), in compliance with continuous disclosure obligations in Canada, t... Read More...
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"

InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol “INM”

VANCOUVER, BC, Nov. 12, 2020 - InMed Pharmaceuticals Inc. ("InMed") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that it has priced a public offering of an aggregate of 1,78... Read More...
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020

InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020

VANCOUVER, BC, Nov. 5, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that, due to the regulatory quiet period the Company is in, ... Read More...
InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

TSX:IN OTCQX:IMLFF VANCOUVER, BC, Nov. 4, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the first quar... Read More...
InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER, BC, Sept. 24, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that all subjects participating in its second P... Read More...
InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

TSX:IN OTCQX:IMLFF VANCOUVER, BC, Sept. 22, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced the filing of a patent applica... Read More...
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

VANCOUVER, BC, Sept. 8, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the fiscal year ended June 30, ... Read More...
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

TSX:INOTCQX:IMLFF  VANCOUVER, BC, Sept. 2, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the fiscal ye... Read More...
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

VANCOUVER, BC, June 19, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a registration statement on Fo... Read More...
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

VANCOUVER, May 19, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced the filing of a key Patent Cooperation Treaty ("PCT") pat... Read More...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

VANCOUVER, May 14, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the third quarter of fiscal year ... Read More...
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

VANCOUVER, May 8, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the third quarter of fiscal year 2020 endi... Read More...
InMed and Almac Group Developing Improved Cannabinoid Production Methods

InMed and Almac Group Developing Improved Cannabinoid Production Methods

VANCOUVER, May 5, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it is working with the Almac Group (UK) ("Almac") on ... Read More...
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

VANCOUVER, April 30, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN;OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced it has received regulatory and ethics board approval ... Read More...
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER, April 1, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that all subjects participating in its 755-101-HV Phase... Read More...
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

VANCOUVER, March 24, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today announced the filing of a Clinical Trial Application ("CTA") in th... Read More...
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

VANCOUVER , March 20, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today provided an update on the impact of the global outbreak of COVID-... Read More...
InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER , March 10, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial... Read More...
InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

- Commenced Dosing of Patients in Phase 1 Clinical Trial with INM-755 - VANCOUVER, Feb. 14, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN),... Read More...
InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020

InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020

VANCOUVER, Feb. 7, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the second quarter of fiscal year 2020... Read More...
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview

InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview

VANCOUVER, Jan. 21, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today published additional information describing in detail its leading... Read More...
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

VANCOUVER, Jan. 20, 2020 - InMed Pharmaceuticals Inc. ("InMed") (TSX:IN;OTCQX:IMLFF), a clinical stage biopharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, today revealed the rare cannabinoid  cannabinol ("CBN") as the active pharmaceutical ingredient ("API") in its two product candidates und... Read More...
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

VANCOUVER, Dec. 9, 2019 - InMed Pharmaceuticals Inc. ("InMed") (TSX: IN;OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced it has received regulatory and ethics board approval of its Clinical Trial Application ("CTA") to condu... Read More...
Coming Soon.

Delayed data (1h)


Share this page